- Home
- KAVL vs SILO Comparison
KAVL vs SILO Comparison
Compare KAVL & SILO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KAVL
- SILO
- Stock Information
- Founded
- KAVL 1998
- SILO 2010
- Country
- KAVL United States
- SILO United States
- Employees
- KAVL N/A
- SILO N/A
- Industry
- KAVL Medicinal Chemicals and Botanical Products
- SILO Apparel
- Sector
- KAVL Health Care
- SILO Consumer Discretionary
- Exchange
- KAVL Nasdaq
- SILO Nasdaq
- Market Cap
- KAVL 6.2M
- SILO 5.9M
- IPO Year
- KAVL N/A
- SILO N/A
- Fundamental
- Price
- KAVL $0.80
- SILO $0.92
- Analyst Decision
- KAVL
- SILO
- Analyst Count
- KAVL 0
- SILO 0
- Target Price
- KAVL N/A
- SILO N/A
- AVG Volume (30 Days)
- KAVL 176.2K
- SILO 201.3K
- Earning Date
- KAVL 11-29-2024
- SILO 11-12-2024
- Dividend Yield
- KAVL N/A
- SILO N/A
- EPS Growth
- KAVL N/A
- SILO N/A
- EPS
- KAVL N/A
- SILO N/A
- Revenue
- KAVL $10,108,906.00
- SILO $72,102.00
- Revenue This Year
- KAVL $652.90
- SILO $1.86
- Revenue Next Year
- KAVL N/A
- SILO N/A
- P/E Ratio
- KAVL N/A
- SILO N/A
- Revenue Growth
- KAVL N/A
- SILO N/A
- 52 Week Low
- KAVL $0.58
- SILO $0.84
- 52 Week High
- KAVL $9.69
- SILO $4.50
- Technical
- Relative Strength Index (RSI)
- KAVL 37.95
- SILO 36.36
- Support Level
- KAVL $0.85
- SILO $1.05
- Resistance Level
- KAVL $0.98
- SILO $1.21
- Average True Range (ATR)
- KAVL 0.07
- SILO 0.12
- MACD
- KAVL -0.02
- SILO -0.03
- Stochastic Oscillator
- KAVL 5.12
- SILO 3.51
About KAVL Kaival Brands Innovations Group Inc.
Kaival Brands Innovations Group Inc is focused on growing and incubating innovative and profitable products. The company is engaged in the sale, marketing and distribution of electronic nicotine delivery system (ENDS) products and related components. Its primary product includes Bidi Stick. The BIDI Stick comes in a variety of flavor options for adult cigarette smokers.
About SILO Silo Pharma Inc.
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders.